Schultheis et al.[20] reported that recurrent ovarian cancer patients with VEGF +937 T polymorphism C/T genotype had a longer PFS when treated with cyclophosphamide and bevacizumab. The gene discussed is VEGFA; the disease is ovarian carcinoma.